178 related articles for article (PubMed ID: 20434006)
1. Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact.
Elice F; Rodeghiero F
Thromb Res; 2010 Apr; 125 Suppl 2():S55-7. PubMed ID: 20434006
[TBL] [Abstract][Full Text] [Related]
2. Hemostatic complications of angiogenesis inhibitors in cancer patients.
Elice F; Jacoub J; Rickles FR; Falanga A; Rodeghiero F
Am J Hematol; 2008 Nov; 83(11):862-70. PubMed ID: 18819092
[TBL] [Abstract][Full Text] [Related]
3. Thrombotic events in patients with cancer receiving antiangiogenesis agents.
Zangari M; Fink LM; Elice F; Zhan F; Adcock DM; Tricot GJ
J Clin Oncol; 2009 Oct; 27(29):4865-73. PubMed ID: 19704059
[TBL] [Abstract][Full Text] [Related]
4. Side effects of anti-angiogenic drugs.
Elice F; Rodeghiero F
Thromb Res; 2012 Apr; 129 Suppl 1():S50-3. PubMed ID: 22682133
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab for advanced breast cancer.
Traina TA; Rugo HS; Dickler M
Hematol Oncol Clin North Am; 2007 Apr; 21(2):303-19. PubMed ID: 17512451
[TBL] [Abstract][Full Text] [Related]
6. Thrombosis associated with angiogenesis inhibitors.
Elice F; Rodeghiero F; Falanga A; Rickles FR
Best Pract Res Clin Haematol; 2009 Mar; 22(1):115-28. PubMed ID: 19285278
[TBL] [Abstract][Full Text] [Related]
7. [Bevacizumab. Progress in cancer therapy by antiangiogenesis].
Krämer I; Lipp HP
Med Monatsschr Pharm; 2006 Jul; 29(7):249-54; quiz 255-6. PubMed ID: 16866078
[TBL] [Abstract][Full Text] [Related]
8. The horizon of antiangiogenic therapy for colorectal cancer.
Olszewski AJ; Grossbard ML; Kozuch PS
Oncology (Williston Park); 2005 Mar; 19(3):297-306; discussion 306, 308, 317-33. PubMed ID: 15828549
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
10. Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis.
van Heeckeren WJ; Sanborn SL; Narayan A; Cooney MM; McCrae KR; Schmaier AH; Remick SC
Curr Opin Hematol; 2007 Sep; 14(5):468-80. PubMed ID: 17934353
[TBL] [Abstract][Full Text] [Related]
11. Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies.
Reinacher-Schick A; Pohl M; Schmiegel W
Nat Clin Pract Gastroenterol Hepatol; 2008 May; 5(5):250-67. PubMed ID: 18382435
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab in the treatment of metastatic colorectal cancer.
Caprioni F; Fornarini G
Future Oncol; 2007 Apr; 3(2):141-8. PubMed ID: 17381413
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab in the treatment of breast cancer.
Koutras AK; Fountzilas G; Makatsoris T; Peroukides S; Kalofonos HP
Cancer Treat Rev; 2010 Feb; 36(1):75-82. PubMed ID: 19932567
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer.
Thornton AD; Ravn P; Winslet M; Chester K
Br J Surg; 2006 Dec; 93(12):1456-63. PubMed ID: 17115389
[TBL] [Abstract][Full Text] [Related]
15. [Anti-angiogenic treatment and colorectal cancer].
André T; Tournigand C; Abbas F; Louvet C; de Gramont A;
Bull Cancer; 2007 Jul; 94 Spec No():S211-9. PubMed ID: 17846007
[TBL] [Abstract][Full Text] [Related]
16. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab (avastin) in ocular processes other than choroidal neovascularization.
Barkmeier AJ; Akduman L
Ocul Immunol Inflamm; 2009; 17(2):109-17. PubMed ID: 19412873
[TBL] [Abstract][Full Text] [Related]
18. Biological mechanisms of bevacizumab-associated adverse events.
Higa GM; Abraham J
Expert Rev Anticancer Ther; 2009 Jul; 9(7):999-1007. PubMed ID: 19589038
[TBL] [Abstract][Full Text] [Related]
19. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
Han ES; Monk BJ
Gynecol Oncol; 2007 Apr; 105(1):3-6. PubMed ID: 17383545
[No Abstract] [Full Text] [Related]
20. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
